SICKLE Cell Disease is an agonising blood condition which affects one in every four West Africans. While it is generally controlled in the western world, a lack of medication and funding in Africa means that victims will regularly die.
Three organisations, the LFSCA, Zankli and Fantsuam Foundation have formed a consortium of Sickle Cell Support organisations, working together to tackle the high level of this disease in northern Nigeria.
Plans have been made to screen 500 children for the disease free of charge – although volunteers are preparing for twice that number. Information about this has been broadcast on radio stations in three different local languages.
All children screened will be given a one-month supply of folic acid and multivitamin tablets. Once test results are known, those affected will be followed up at the Kafanchan Sickle Cell Clinic with psycho-social and medical support. The awareness days will also offer counselling and videos to tackle the many myths which surround the disorder.
Fantsuam Foundation would therefore like to offer the opportunity to sponsor any part of the following. The Screening tent and banners; provision of company/individual labelled bottled water which will be used during and after the event (an increased intake of water can help prevent crises in Sickle Cell patients).
In addition, they require support for the Penicillin V and Mosquito Net Fund for Sickle Cell Patients; the cost of rental for buses to take participants on a slow ride through Kafanchan town; 2 travel tickets for Diaspora experts to and from Nigeria; and hotel accommodation for four overseas experts in Abuja for one week.
Companies and individuals will have the opportunity for exhibition and/or be acknowledged in their final report to the United Nations Development Project.
Should you welcome the opportunity to discuss this or have any further queries please contact email@example.com in the first instance. For additional information and/or to make a donation please see our Dadamac Sickle Cell Project page.